Clinical Trials Browser

Terminated × Stomach Neoplasms × 30 days × Clear all

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colonic Neoplasms, Esophageal Neoplasms, Kidney Neoplasms, Recurrence, Stomach Neoplasms

NCT04600466 2026-04-14

Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer

Terminated

129 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05567835 2026-04-09

TOGAR

Phase 2 Terminated

3 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04931823 2026-04-03

Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

Phase 1 Terminated

34 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT04234113 2026-03-27

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Phase 1 Terminated

115 enrolled 43 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Clinical Trials

JIVAN

Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer

TOGAR

Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors